8-(p-Tolyl)theophylline | 57196-70-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 8-(p-Tolyl)theophylline
• 英文别名: 8-(4-methylphenyl)-1,3-dimethyl-1H-purine-2,6(3H,7H)-dione；N1,N3-dimethyl-8-p-methylphenylxanthine；1,3-dimethyl-8-p-tolyl-3,7-dihydro-purine-2,6-dione；1,3-Dimethyl-8-(4-methyl)phenyl-xanthine；8-(4'-Methylphenyl)-theophyllin；8-p-Tolyl-1,3-dimethyl-xanthin；1,3-Dimethyl-8-p-tolyl-3,7-dihydro-purine-2,6-dione；1,3-dimethyl-8-(4-methylphenyl)-7H-purine-2,6-dione
• CAS: 57196-70-0
• 化学式: C₁₄H₁₄N₄O₂
• 分子量: 270.291
• InChiKey: XAMDGANBXINPSA-UHFFFAOYSA-N

物化性质

• 熔点：
  375-380 °C
• 沸点：
  518.9±52.0 °C(Predicted)
• 密度：
  1.321±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  69.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  5,6-二氨基-1,3-二甲基脲嘧啶 在 间氯过氧苯甲酸 作用下， 以 乙醇 、 乙腈 为溶剂， 生成 8-(p-Tolyl)theophylline
  参考文献：
  名称：

  De Araujo, Aline D.; Bacher, Edmond; Joachim Demnitz, Heterocycles, 1999, vol. 51, # 1, p. 29 - 36

  摘要：

  DOI：

文献信息

• Pyrimidine derivatives and related compounds. Part 47. A new synthesis of xanthines and pyrrolo[3,2-d]pyrimidines by intramolecular cyclisation of 6-substituted 5-nitrouracil derivatives
  作者：Kosaku Hirota、Tadashi Sugiyama、Yukio Kitade、Shigeo Senda、Yoshifumi Maki

  DOI：10.1039/p19840000583

  日期：——

  of 6-[2-(ethoxycarbonyl, acetyl, and cyano) ethyl] uracil (8h–j) with triethylamine led to the formation of the corresponding 6-vinyluracil (11 a–c). A one-step synthesis of the 7-hydroxy-9-deazaxanthines (9a–e) was accomplished by the treatment of the sodium salt (7) with arylalkyl chlorides in the presence of potassium carbonate in dry DMF. Deoxygenation of the 7-hydroxy-9-deazaxanthines (9a–e) smoothly

  通过在三乙胺存在下使6-氯-1,3-二甲基-5-硝基尿嘧啶（1）与芳基烷基胺反应，制得6-芳烷基氨基-1,3-二甲基-5-硝基尿嘧啶（2a–f）。其中，在氮原子和6-芳基烷基氨基部分中的苄基位置不具有取代基的6-芳基烷基氨基尿嘧啶（2a–d）在转化为相应的8-芳基-1,3-二甲基黄嘌呤（3a–d）时在二甲基甲酰胺（DMF）中加热回流。钠盐（反应7 1,3,6-三甲基-5- nitrouracil（的）6）用在无水DMF烷基和芳基烷基卤化物，得到相应的6-（取代甲基）-1,3-二甲基-5-硝基尿嘧啶（8a–j）。其中，对6-（2-芳基乙基）尿嘧啶（8b-f）进行碱催化的环化反应，得到8-芳基-7-羟基-9-脱氮黄嘌呤（9a-e）。另一方面，用三乙胺处理6- [2-（乙氧羰基，乙酰基和氰基）乙基]尿嘧啶（8h-j）导致形成相应的6-乙烯基尿嘧啶（11a-c）。在干燥的DMF中，在碳酸钾的存在下
• Xanthines in the 7th position with a benzyl acetic acid moiety
  申请人：Bayer Aktiengesellschaft

  公开号：US05714494A1

  公开（公告）日：1998-02-03

  Substituted xanthines of formula ##STR1## in which A represents a radical of the formula ##STR2## in which R.sup.3, R.sup.4, R.sup.6 and R.sup.7 denote hydrogen, cycloalkyl, aryl having 6 to 10 carbon atoms, or denote straight-chain of branched alkyl or alkenyl, each of which is optionally substituted; T, V, X and Y are identical or different and denote an oxygen or sulphur atom; R.sup.5 and R.sup.8 are identical or different and denote hydrogen, halogen, cycloalkyl having 3 to 8 carbon atoms or straight-chain or branched alkyl or alkenyl in each case having up to 8 carbon atoms, optionally substituted or R.sup.5 and R.sup.8 denote aryl having 6 to 10 carbon atoms or a 5- to 7-membered aromatic, optionally benzo-fused heterocycle having up to 3 heteroatoms S, N and/or O, each of which is optionally substituted; L represents an oxygen or sulphur atom; R.sup.2 represents mercapto, hydroxyl, straight-chain or branched alkoxy having up to 8 carbon atoms or the group of the formula ##STR3## in which R.sup.13 denotes hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms; R.sup.14 denotes hydrogen, phenyl or a 5- to 6-membered aromatic heterocycle having up to 3 heteroatoms S, N and/or O; and R.sup.15 denotes hydrogen or straight-chain or branched alkyl having up to 8 carbon atom, optionally substituted by hydroxyl, and their salts are prepared by reaction of the suitable unsubstituted xanthines with halogenomethylphenylacetic acids and subsequent reaction of the carboxylic esters or acids with phenylglycinolamine. The substituted xanthines are suitable as active compounds in medicaments, in particular in antiatherosclerotic medicaments.

  公式为##STR1##的黄嘌呤衍生物，其中A代表##STR2##的基团，其中R.sup.3、R.sup.4、R.sup.6和R.sup.7表示氢、环烷基、含有6至10个碳原子的芳香族，或表示直链或支链烷基或烯基，每个基团可选地被取代；T、V、X和Y相同或不同，表示氧或硫原子；R.sup.5和R.sup.8相同或不同，表示氢、卤素、含有3至8个碳原子的环烷基或直链或支链烷基或烯基，每种情况下最多含有8个碳原子，可选地被取代，或R.sup.5和R.sup.8表示含有6至10个碳原子的芳香族或含有最多3个杂原子S、N和/或O的5至7元芳香族，可选地被取代；L表示氧或硫原子；R.sup.2表示巯基、羟基、最多含有8个碳原子的直链或支链烷氧基或##STR3##的基团，其中R.sup.13表示氢或最多含有4个碳原子的直链或支链烷基；R.sup.14表示氢、苯基或含有最多3个杂原子S、N和/或O的5至6元芳香族杂环；R.sup.15表示氢或最多含有8个碳原子的直链或支链烷基，可选地被羟基取代，以及它们的盐是通过将适当的未取代黄嘌呤与卤代甲基苯乙酸反应，然后将羧酸酯或酸与苯基甘氨醇胺反应制备的。这些取代的黄嘌呤适用作为药物中的活性化合物，特别是适用于抗动脉粥样硬化药物。
• Low glycemic response compositions
  申请人：The Procter & Gamble Co.

  公开号：US20020187219A1

  公开（公告）日：2002-12-12

  The present disclosure is related to compositions useful in the field of foods and beverages. In particular, the present invention relates to those compositions that reduce the postprandial rise in blood glucose (described as low Glycemic Index) that synergistically provide enhanced metabolism in the mammalian system and inhibit the storage of systemic fat. In particular, the present invention relates to compositions comprising: a) one or more flavanols; b) one or more bracers; and c) vitamin B; wherein the composition exhibits a Glycemic Index of about 55 or less. As disclosed, the unique combination of ingredients, which provide the defined, low Glycemic Index, work synergistically together to enhance perception of energy and/or improve physiological energy via metabolism enhancement over a long duration of time, without resulting in sudden peaks of glucose in the mammalian system. Thus, the present compositions effectively modulate glucose in the system, thereby providing energy to the system without resulting in the storage of systemic fat.

  本公开涉及在食品和饮料领域有用的组合物。特别是，本发明涉及那些能够减少餐后血糖上升（描述为低升糖指数）的组合物，这些组合物在哺乳动物系统中协同作用，提供增强的代谢作用并抑制系统性脂肪的储存。特别是，本发明涉及包括：a）一种或多种黄烷醇；b）一种或多种支链氨基酸；和c）维生素B的组合物；其中该组合物表现出约55或更低的升糖指数。如本文所述，这些独特的成分组合，以定义的低升糖指数为特征，协同作用，能够提高能量感知和/或通过代谢增强长时间改善生理能量，而不会导致哺乳动物系统中的血糖突然峰值。因此，本组合物有效地调节系统中的葡萄糖，从而为系统提供能量而不导致系统性脂肪的储存。
• Compositions, kits, and methods for promoting defined health benefits
  申请人：——

  公开号：US20030069202A1

  公开（公告）日：2003-04-10

  The present invention is directed to compositions comprising: (a) a first component selected from the group consisting of gelatin, cartilage, aminosugars, glycosaminoglycans, methylsulfonylmethane, precursors of methylsulfonylmethane, S-adenosylmethionine, salts thereof, and mixtures thereof; and (b) a second component comprising: (i) a cation source selected from the group consisting of calcium, potassium, magnesium, and mixtures thereof; and (ii) an edible acid source. The present invention is further directed to food, beverage, pharmaceutical, over-the- counter, and dietary supplement products, which comprise the present compositions. The invention also relates to kits comprising the present compositions and information that use of the composition promotes one or more of the presently defined health benefits, including joint health, bone health, cardiac health, and anti-inflammation. The present invention additionally relates to methods of treating joint function, bone function, cardiac function, or inflammation comprising administering to a mammal a composition as defined herein.

  本发明涉及包括以下组分的组合物：(a)从明胶、软骨、氨基糖、糖胶质、甲基磺酰甲烷、甲基磺酰甲烷的前体、S-腺苷甲硫氨酸、其盐和其混合物中选择的第一组分; 和(b)包括：(i)从钙、钾、镁和其混合物中选择的阳离子源; 和(ii)可食用的酸源的第二组分。本发明还涉及包含本组合物的食品、饮料、制药、非处方药和膳食补充剂产品。本发明还涉及包含本组合物和使用该组合物促进当前定义的健康益处之一或多个的信息的套件。本发明还涉及治疗关节功能、骨功能、心脏功能或炎症的方法，包括向哺乳动物投与本文所定义的组合物。
• Beverage compositions comprising arabinogalactan and defined vitamins
  申请人：The Procter & Gamble Co.

  公开号：US20020110632A1

  公开（公告）日：2002-08-15

  The present invention is directed to compositions comprising: a) a first component which is arabinogalactan; and b) a second component comprising two or more vitamins selected from the group consisting of vitamin A, vitamin C, vitamin D, vitamin E, and B-complex vitamins. In an alternative embodiment of the present invention, the compositions comprise: a) a first component which is arabinogalactan; and b) a second component comprising one or more vitamins selected from the group consisting of vitamin A, vitamin D, and vitamin E. The present compositions are useful to provide beverages which increase the solubility of fat-soluble vitamins, and deliver the benefits of fiber, one or more of the defined vitamins, and/or provide other health benefits, including fighting infection, promoting healthy bacteria, and providing a desired dietary fiber benefit. Additionally, the present invention provides beverage compositions having excellent taste, and other organoleptic properties, despite the inclusion of the fiber and vitamin components. These and other benefits of the present invention are described herein.

  本发明涉及包括：a）阿拉伯半乳糖和b）由维生素A、维生素C、维生素D、维生素E和B族维生素中选择两种或更多种组成的第二组分的组合物。在本发明的另一实施例中，组合物包括：a）阿拉伯半乳糖和b）由维生素A、维生素D和维生素E中选择一种或多种组成的第二组分。本组合物有助于提供增加脂溶性维生素溶解度的饮料，并提供纤维、一个或多个定义的维生素的益处和/或提供其他健康益处，包括抗感染、促进健康细菌和提供所需的膳食纤维益处。此外，本发明提供了具有出色口感和其他感官特性的饮料组合物，尽管包括纤维和维生素成分。本发明的其他优点在此描述。